A new and faster way of measuring kinetics to accelerate drug discovery Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announced the launch of waveRAPID® (Repeated Analyte Pulses of Increasing Duration), a novel, label-free kinetic measurement method that is faster than traditional kinetics. This is a product release announcement by Creoptix AG. The issuer is solely responsible for its content. The company developed and commercializes the Creoptix® WAVEsystem to enable molecular interactions to be studied in real time, helping to revolutionize drug discovery. By bringing together modern label-free technology, application development know-how and sophisticated software, Creoptix offers a unique optical biosensor tool for binding kinetics. Engineered around its proprietary Grating-Coupled Interferometry (GCI) technology, the system achieves superior resolution in terms of signal and speed compared to traditional Surface Plasmon Resonance (SPR). With the latest Creoptix innovation, researchers using waveRAPID® can now select drug candidates more accurately with both binding kinetics and affinity data.